Chest
Selected ReportsAcute Pulmonary Hypersensitivity to Carbamazepine
Section snippets
CASE REPORT
A 55-year-old black woman was referred on October 19, 1973, for evaluation and treatment of right-sided trigeminal neuralgia. Treatment was begun with carbamazepine, 100 mg twice daily, after hepatic and hematologic profiles were reported as normal. The patient improved symptomatically; three weeks later the dosage was raised to 200 mg twice daily. Hepatic and hematologic studies were again normal.
Two weeks after this, she came to the emergency room with a three-day history of cough, shortness
DISCUSSION
We believe that the case described represents pulmonary hypersensitivity to carbamazepine that manifested itself as an acute, moderately debilitating systemic illness with prominent pulmonary alterations, skin rash, and eosinophilia. To our knowledge, there has been no previous case report of pulmonary hypersensitivity to carbamazepine. After the cessation of carbamazepine therapy, the patient improved markedly within three days, but the pulmonary radiographic findings showed delayed
ACKNOWLEDGMENT
Dr. Sam Yanari performed the lymphocyte transformation tests.
References (7)
- et al.
Carbamazepine for epilepsy: A controlled evaluation
Neurology
(1974) Carbamazepine
Ann Intern Med
(1973)Drug-induced lung disease: The price of progress: Medical staff conference, University of California, San Francisco
Calif Med
(1973)
Cited by (26)
Psychiatric medications: Adverse cutaneous drug reactions
2013, Clinics in DermatologyDrug-induced eosinophilic lung disease
2004, Clinics in Chest MedicineMetastatic squamous cell carcinoma with marked blood eosinophilia and elevated serum interleukin-5 levels
2002, Experimental HematologyAcute lung toxicity induced by carbamazepine: A case report
1994, Archivos de BronconeumologiaHypersensitivity pneumonitis
1991, Disease-a-Month